Andersen-Tawil syndrome

Indian Pacing and Electrophysiology Journal

Volumn 6, Issue 1, 2006, Pages 32-43

  Smith, Andrew H ^a   Fish, Frank A ^a   Kannankeril, Prince J ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

Andersen Tawil syndrome; Arrhythmias; Genetics; Ion channels

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLECAINIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; MEXILETINE; NICORANDIL; ORAL CONTRACEPTIVE AGENT; POTASSIUM; PROPAFENONE; PROPRANOLOL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SPIRONOLACTONE;

ALPHA CHAIN; ANDERSEN SYNDROME; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL FEATURE; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE EXACERBATION; FACE DYSMORPHIA; GENETIC CODE; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; HEART EXCITATION; HEART MUSCLE POTENTIAL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; MOLECULAR GENETICS; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; PERIODIC PARALYSIS; RARE DISEASE; REVIEW; SODIUM RESTRICTION; SYMPTOMATOLOGY; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 30544435329     PISSN: 09726292     EISSN: 09726292     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, Griggs RC. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35:326-330.
2. Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL, Jr., Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptacek LJ. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105:511-519.
3. Klein R, Ganelin R, Marks JF, Usher P, Richards C. J Periodic paralysis with cardiac arrhythmia. J Pediatr. 1963;62:371-385.
4. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand. 1971;60:559-564.
5. Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, Suarez WA, Cobo AM, Poza JJ, Behr E, Wagstaff J, Szepetowski P, Pereira S, Mozaffar T, Escolar DM, Fu YH, Ptacek LJ. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology. 2003;60:1811-1816.
6. Ptacek LJ, George AL, Jr., Griggs RC, Tawil R, Kallen RG, Barchi RL, Robertson M, Leppert MF. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991;67:1021-1027.
7. Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med. 2004;36 Suppl 1:92-97.
8. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, Bendahhou S, Kwiecinski H, Fidzianska A, Plaster N, Fu YH, Ptacek LJ, Tawil R. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002;110:381-388.
9. Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL, Jr., Benson DW. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet. 2002;71:663-668.
10. Canun S, Perez N, Beirana LG. Andersen syndrome autosomal dominant in three generations. Am J Med Genet. 1999;85:147-156.
11. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, George AL, Horie M, Andelfinger G, Snow GL, Fu YH, Ackerman MJ, Vincent GM. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation. 2005;111:2720-2726.
12. Chun TU, Epstein MR, Dick M, Andelfinger G, Ballester L, Vanoye CG, George AL, Jr., Benson DW. Polymorphic ventricular tachycardia and KCNJ2 mutations. Heart Rhythm. 2004;1:235-241.
13. Levitt LP, Rose LI, Dawson DM. Hypokalemic periodic paralysis with arrhythmia. N Engl J Med. 1972;286:253-254.
14. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol. 2005.
15. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol. 2004;15:119.
16. Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med. 2001;110:385-398.
17. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025-2032.
18. Piccini J, Zaas A. Cases from the Osler Medical Service at Johns Hopkins University. Digitalis toxicity with bidirectional ventricular tachycardia. Am J Med. 2003;115:70-71.
19. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200.
20. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339:960-965.
21. Kubo Y, Baldwin TJ, Jan YN, Jan LY. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature. 1993;362:127-133.
22. Raab-Graham KF, Radeke CM, Vandenberg CA. Molecular cloning and expression of a human heart inward rectifier potassium channel. Neuroreport. 1994;5:2501-2505.
23. Roden DM, George AL, Jr. Structure and function of cardiac sodium and potassium channels. Am J Physiol. 1997;273:H511-H525.
24. Dhamoon AS, Jalife J. The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm. 2005;2:316-324.
25. Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron. 2002;34:933-944.
26. Miake J, Marban E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest. 2003;111:1529-1536.
27. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, Napolitano C, Anumonwo J, di Barletta MR, Gudapakkam S, Bosi G, Stramba-Badiale M, Jalife J. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800-807.
28. Yang J, Jan YN, Jan LY. Determination of the subunit stoichiometry of an inwardly rectifying potassium channel. Neuron. 1995;15:1441-1447.
29. Preisig-Muller R, Schlichthorl G, Goerge T, Heinen S, Bruggemann A, Rajan S, Derst C, Veh RW, Daut J. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci U S A. 2002;99:7774-7779.
30. Lange PS, Er F, Gassanov N, Hoppe UC. Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion. Cardiovasc Res. 2003;59:321-327.
31. Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002;59:466.
32. Haissaguerre M, Extramiana F, Hocini M, Cauchemez B, Jais P, Cabrera JA, Farre J, Leenhardt A, Sanders P, Scavee C, Hsu LF, Weerasooriya R, Shah DC, Frank R, Maury P, Delay M, Garrigue S, Clementy J. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925-928.
33. Sanders P, Hsu LF, Hocini M, Jais P, Takahashi Y, Rotter M, Sacher F, Pasquie JL, Arentz T, Scavee C, Garrigue S, Clementy J, Haissaguerre M. Mapping and ablation of ventricular fibrillation. Minerva Cardioangiol. 2004;52:171-181.
34. Takahashi T, Tandai S, Toki T, Sato T, Eto S, Sato A, Ueda T, Sato S, Ichinose K, Ito E, Yonesaka S. KCNJ2 mutation in intractable ventricular arrhythmia with Andersen's syndrome. Pediatr Int. 2005;47:220-223.
35. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-1583.
36. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL, Gibbons RJ, Antman EM, Alpert JS, Gregoratos G, Hiratzka LF, Faxon DP, Jacobs AK, Fuster V, Smith SC, Jr. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145-2161.
37. Kannankeril PJ, Fish FA. Antitachycardia pacing safely reduces shocks in pediatric patients with hypertrophic cardiomyopathy or primary electrical disease. Heart Rhythm. 2005;2:S211.